Please assess the completion status of the following clinical trial:

Trial Title: Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 year~2. Patients underwent pancreaticoduodenectomy~3. Fistula Risk Score recommended by ISGPS is intermediate risk~4. Inform consent obtained~Exclusion Criteria:~1. Pervious pancreatic surgery history~2. Received somatostatin or analogues treatment less than 5 half-life periods before surgery~3. Known allergy to somatostatin or mannitol~4. Woman who is pregnant, plan to be pregnant or during lactation period~5. Attended other clinical trials within 30 days~6. All contraindications to somatostatin (Stilamin®)~7. Patients with any serious disease that investigator considers he/she should be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stilamin group (Type: EXPERIMENTAL): Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin in addition to postoperative conventional treatment.
- Control group (Type: NO_INTERVENTION): Patients in the control group will receive the postoperative conventional treatment, without addition of any new medicines.

Based on this trial design, predict the completion outcome and termination type (if applicable).